Subthreshold laser treatment with Endpoint Management in posterior pole diseases associated with sub- and intraretinal fluid.

Augenklinik der Ludwig-Maximilians Universität München0 个研究点目标入组 50 人开始时间: 2018年9月5日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Age =18 years, ability to give consent must be given, ability to participate in studies on a
•regular basis must be given, BCVA better than 0,05, Diagnosis of optic disc pit maculopathy, exsudative choroidal naevus, MacTel type 2 or
•persistent subretinal fluid after retinal detachment surgery (vitrectomy or buckling)
•confirmed by retinal specialist, Normal findings in the medical history unless the investigator considers an abnormality to be
•clinically irrelevant

•Any other macular disease with possibility of developing subretinal fluid: vitreomacular traction syndrome, epiretinal membranes, age-related macular degeneration, diabetic retinopathy, choroidal neovascularization, uveitis, Ocular surgery for 3 months preceding the study, Previous intravitreal injections of anti-VEGF, steroids within 3 months preceding the study, Previous macular laser treatment or photodynamic therapy within 6 months preceding the study, Present ocular infection or clinically significant inflammation, Kidney failure or dialysis, Women: Pregnancy or currently breast-feeding ,Allergy to fluorescein, History of systemic or topical corticosteroid use within last 6 months, Patient is not able to cooperate or has any other medical or psychological condition that prohibits him from regular follow-up, Planned intraocular surgery within 12 months

发起方

Augenklinik der Ludwig-Maximilians Universität München